« Back to News

Press Release

Casebia Announces Appointment of New SVP, Head of Technical Operations

Stephen Kennedy to join Casebia’s growing leadership team to lead the company’s development and manufacturing department

CAMBRIDGE, Mass., June 4, 2019Casebia Therapeutics, an innovative gene editing company discovering and developing curative treatments for genetic diseases, today announced it has appointed Stephen Kennedy as Senior Vice President, Head of Technical Operations. He joins a robust leadership team that includes some of the top leaders from the growing gene editing industry.

Steve has more than 30 years of experience in the fields of manufacturing and development of biopharmaceutical innovations and emerging technologies. He is a respected leader in the field, and is poised to play an important role leading Casebia’s process development and manufacturing strategy for the company’s gene editing programs. He will oversee the company’s relationships with CROs and CMOs, will direct all manufacturing and will support supply chain, quality and regulatory.

“This hiring of Steve is an embodiment of Casebia’s forward thinking in the gene editing space,” said Jim Burns, Ph.D., CEO of Casebia Therapeutics. “We are excited to bring on a dedicated leader who will play a key role in our company as we advance our product candidates and move toward the clinic.”

In his role at Casebia, Steve will establish the process development and manufacturing strategy for new gene editing-based products, both ex vivo cell-based and in vivo therapies. He will also head the internal process development and manufacturing function in the company, and direct all process development, technology transfer, manufacturing and supply chain for all preclinical and clinical product development and commercial supply.

Before joining Casebia, Steve served as the Chief Operating Officer for Histogenics Corporation, a restorative cell therapy company. Prior to his time at Histogenics, he spent three years as the Executive Vice President of Research and Development at Mascoma Corp., and one year as the Executive Director at The Novartis/MIT Center for Continuous Manufacturing. Steve spent over a decade at Genzyme where he worked his way up to Senior Vice President of Biologics Operations, where he oversaw the development of therapeutic protein capacity for the company. His experience spans the globe as he’s held positions in Finland, France and Belgium.

Steve holds a Bachelor of Science in Chemical Engineering from The University of Michigan. He then earned his M.S. in Chemical Engineering from the University of Rochester, and his Master of Business Administration from Boston University.

About Casebia Therapeutics

Casebia Therapeutics is a novel joint venture between Bayer and CRISPR Therapeutics, formed in 2016 to advance CRISPR/Cas9 gene-editing therapeutics to discover and develop curative treatments for patients suffering from genetic diseases of the eye, ear and blood, as well as autoimmune, metabolic and cardiovascular conditions. The Casebia technology platform is moving genetic medicine forward by enabling new genetic engineering tools and revolutionary delivery methods for gene editing that target treatments precisely to specific areas of the body affected by disease. Casebia’s headquarters are in Cambridge, MA, with a research center in San Francisco, CA. For more information, please visit www.casebia.com or follow us at on Twitter @casebiatx.

###

Media Contact:

For Casebia:
Travis Small
617-538-9041
tsmall@sloweymcmanus.com